A Scarcity of Biotech Assets for Buyouts?
May 20, 2016 at 12:06 PM EDT
Gabelli's Jing He argues that a "scarcity of valuable biotech assets" available for purchase by bigger biotech and pharmaceutical companies should keep a floor under Medivation ( MDVN )--and by implication BioMarin Pharmaceutical ( BMRN ), Incyte ( INCY ) and Seattle Genetics ( SGEN ). She explains why:
